Pfizer Inc. (NYSE:PFE) Shares Bought by Nicholas Hoffman & Company LLC.

Nicholas Hoffman & Company LLC. raised its position in Pfizer Inc. (NYSE:PFE) by 6.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,230 shares of the biopharmaceutical company’s stock after acquiring an additional 2,730 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in Pfizer were worth $1,238,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $16,166,000. First Heartland Consultants Inc. grew its position in shares of Pfizer by 43.3% during the fourth quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 3,933 shares in the last quarter. ORG Partners LLC grew its position in shares of Pfizer by 1,729.9% during the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 44,458 shares in the last quarter. Kempner Capital Management Inc. acquired a new stake in shares of Pfizer during the first quarter worth approximately $2,439,000. Finally, Leo Wealth LLC acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $2,171,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock traded up $0.21 during midday trading on Thursday, hitting $28.60. The company’s stock had a trading volume of 7,089,055 shares, compared to its average volume of 38,254,461. The stock’s 50-day moving average price is $29.03 and its 200-day moving average price is $28.04. The company has a market capitalization of $162.06 billion, a PE ratio of -472.92, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $35.28. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter last year, the business posted $0.67 EPS. Pfizer’s revenue was up 2.1% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were paid a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.87%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, August 19th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Wells Fargo & Company raised their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.